Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
life sciences
bioinnovation capital
biolabs
boston top stories
brexanalone
chemotherapy
clinical data
daraprim
depression
drug pricing
drugs
epipen
epipens
exome
gene therapy
generic drugs
insulin
jeff jonas
johannes fruehauf
labcentral
life science
major depressive disorder
martin shkreli
mental illness
mylan
national blog main
national top stories
national xcon
neuroscience
novartis
oncology
peter kolchinsky
phase 3 trial
postpartum depression
price collusion
psychiatric disorders
sage therapeutics
What
drug
2
×
medical
2
×
approval
biotech
brexanalone
depression
driving
fda
good
healthcare
history
hits
hour
improved
industry
infusion
innovation
innovations
investment
life
long
mark
outcomes
phase
postpartum
ppd
pricing
proud
public
sage
sciences
soon
stock
supervised
surges
therapeutics
trial
wide
win
Language
unset
Current search:
boston
×
drug
×
medical
×
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
